- Home
- KLG vs VCEL Comparison
KLG vs VCEL Comparison
Compare KLG & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLG
- VCEL
- Stock Information
- Founded
- KLG 2022
- VCEL 1989
- Country
- KLG United States
- VCEL United States
- Employees
- KLG N/A
- VCEL N/A
- Industry
- KLG Packaged Foods
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KLG Consumer Staples
- VCEL Health Care
- Exchange
- KLG Nasdaq
- VCEL Nasdaq
- Market Cap
- KLG 2.0B
- VCEL 2.1B
- IPO Year
- KLG N/A
- VCEL 1997
- Fundamental
- Price
- KLG $22.97
- VCEL $34.05
- Analyst Decision
- KLG Hold
- VCEL Strong Buy
- Analyst Count
- KLG 7
- VCEL 6
- Target Price
- KLG $20.57
- VCEL $61.50
- AVG Volume (30 Days)
- KLG 960.0K
- VCEL 565.9K
- Earning Date
- KLG 08-07-2025
- VCEL 07-31-2025
- Dividend Yield
- KLG 2.88%
- VCEL N/A
- EPS Growth
- KLG N/A
- VCEL 2045.40
- EPS
- KLG 0.35
- VCEL 0.13
- Revenue
- KLG $2,605,000,000.00
- VCEL $249,119,000.00
- Revenue This Year
- KLG N/A
- VCEL $18.35
- Revenue Next Year
- KLG N/A
- VCEL $22.47
- P/E Ratio
- KLG $66.39
- VCEL $256.98
- Revenue Growth
- KLG N/A
- VCEL 16.13
- 52 Week Low
- KLG $14.80
- VCEL $33.09
- 52 Week High
- KLG $23.56
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- KLG 63.02
- VCEL 40.14
- Support Level
- KLG $22.87
- VCEL $33.34
- Resistance Level
- KLG $22.99
- VCEL $36.81
- Average True Range (ATR)
- KLG 0.07
- VCEL 1.36
- MACD
- KLG -0.12
- VCEL -0.13
- Stochastic Oscillator
- KLG 52.63
- VCEL 20.14
About KLG WK Kellogg Co
WK Kellogg is the second-largest cereal manufacturer in North America. Its cereal brands include Special K, Frosted Flakes, Raisin Bran, Froot Loops, Frosted Mini-Wheats, Kashi, Corn Flakes, Rice Krispies, Apple Jacks, and Bear Naked. The company was spun off from the former Kellogg business, now known as Kellanova, where the former firm's global snacks portfolio and international cereal brands now reside. WK Kellogg, which began trading independently in October 2023, generates the bulk of its sales (about 88% of its fiscal 2024 base) in the US.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.